Cargando…
5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer
AIMS: 5-FU is used as the main backbone of chemotherapy regimens for patients with colorectal and other gastrointestinal cancers. Despite development of new strategies that allowed enhancing clinical effectiveness and tolerability of 5-FU, 10–30% of patients treated with 5-FU-based regimens experien...
Autores principales: | Morawska, Katarzyna, Goirand, Françoise, Marceau, Laurine, Devaux, Madeline, Cueff, Adèle, Bertaut, Aurélie, Vincent, Julie, Bengrine-Lefevre, Leila, Ghiringhelli, François, Schmitt, Antonin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837758/ https://www.ncbi.nlm.nih.gov/pubmed/29545919 http://dx.doi.org/10.18632/oncotarget.24338 |
Ejemplares similares
-
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020) -
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019) -
Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016) -
Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017) -
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Bellio, Hélène, et al.
Publicado: (2021)